Thomas Jordan

Partner

Bristol

Thomas Jordan is a personal injury lawyer in our Bristol office. He specialises in industrial disease litigation.
Successfully added
Failed to add

About Thomas

Bio
  • Biography

    Thom specialises in occupational disease litigation with specific focus on asbestos related conditions and new and emerging risks.

    He has over 10 years’ experience advising clients across a range of sectors including construction, manufacturing and the public sector. His key clients include Zurich Insurance plc.

    Thom helps clients manage high value complex disease claims, finding practical and cost effective ways of resolving litigation.  

    Relevant experience includes:

    • Acting in respect of a group claim of over 100 claimants resulting from exposures to harmful fumes and vapours in the workplace.
    • Representing a defendant employer in respect of a group claim of 13 claimants for workplace exposures with a combined claims value in excess of £1 million.
    • Numerous long term secondments to various insurer clients assisting with EL/PL and disease cases.
Sector Expertise
  • Insurance

Service Expertise
  • UK Casualty

  • Disease

Office Location

Bristol Skyline

Bristol

  • DAC Beachcroft LLP
  • Portwall Place, Portwall Lane
  • Bristol, BS1 6NA

+44 (0) 117 918 2000

View our office

Articles

There are no matching articles, please try a different filter.

Article

7 min read

Bringing down the curtain on a class of mesothelioma claims

Insurance

9 min read

Disease Claims - New Guidelines for the Assessment for General Damages in Northern Ireland

Health and Social Care

4 min read

Monkeypox: What is it and what are the risks?

Article

4 min read

COVID-19: The Ending of Restrictions in England and Wales

Insurance

10 Min Read

Disease update Q4 2022

Insurance

20 min read

Disease Update Q3 2021

Insurance

31 min read

Disease Update 2021 Q1 and Q2

Insurance

22 min read

Disease Update: 2021 Q4

Insurance

19 min read

Disease Update: 2020 Q3

Insurance

14 min read

Disease Update: 2020 Q2